ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
Natural Capsules Limited is holding a board meeting at shorter notice on September 02, 2026, to revise the issue price and quantity for its proposed preferential issue.
Natural Capsules Limited has issued a notice for an EGM to approve a Rs. 10.00 Crore preferential allotment of equity shares and warrants to a promoter.
NCL reported Q1FY27 revenue of ₹48.71 Cr (+8% Y-o-Y) with EBITDA at ₹1.12 Cr. Strategy focuses on scaling steroidal API volumes and HPMC line conversions to optimize capacity.
Natural Capsules Limited announced its Q1FY27 financial results. The company highlighted operational performance, market demand, and new contract manufacturing agreements for its business segments.
Natural Capsules Limited announced the appointment of Mr. K. H. Honneshaiah as the new Chief Operating Officer of its material unlisted subsidiary, Natural Biogenex Private Limited.
Natural Capsules Ltd reported revenue from operations of ₹48.7 Cr (+7.7% YoY) and a net loss of ₹5.7 Cr for Q1 FY27.
Natural Capsules Limited held its 33rd Annual General Meeting on August 12, 2026, via video conferencing. The meeting covered agenda items including adoption of financial statements and director re-appointments.
Natural Capsules Ltd scheduled a board meeting for August 12, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Natural Capsules Ltd's subsidiary, Natural Biogenex, allotted 9.46 lakh equity shares at par via a rights issue, aggregating to ₹0.95 Crore.
Natural Capsules decided not to participate in its subsidiary Natural Biogenex's Rights Issue. Consequently, the company's stake in the subsidiary will dilute by 2.18%.
Natural Capsules Limited released its FY2025-26 Annual Report. The company expanded installed capsule capacity to 20.25 BCPA and commenced commercial production at its Tumkur API facility.
Natural Capsules Limited convened its 33rd AGM for August 12, 2026. Agenda items include approving Rs. 50 Crore in related party transactions and director re-appointments.
Natural Capsules Limited scheduled its 33rd AGM for August 12, 2026. The record date for meeting participation is August 05, 2026.
Natural Biogenex Private Limited approved a rights issue worth Rs 1.12 Crore. The issue involves 11,16,766 equity shares at par value.
Natural Capsules' subsidiary, Natural Biogenex, approved the allotment of 1,11,202 equity shares via rights issue. The transaction is valued at Rs. 0.11 Crore.
Natural Capsules Ltd reported Q4 FY26 revenue of ₹58.45cr (up 55% QoQ). Full-year FY26 revenue grew 11% to ₹187.20cr, though the company posted a net loss of ₹24.66cr.
Natural Capsules reports Q4FY26 revenue of ₹58.45 Cr (+30% Y-o-Y) while facing a PAT loss of ₹4.98 Cr. Strategy focuses on steroidal API scaling and HPMC capsule expansion.
Natural Capsules Limited reported Q4FY26 revenue of ₹58.45 Crore and annual revenue of ₹187.20 Crore. The company successfully resumed dispatches following a plant shutdown.
Natural Capsules Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms general regulatory adherence under SEBI guidelines.
Natural Capsules Limited appointed Akshay Dutta as Company Secretary and re-appointed Laxminarayan Moondra as Whole Time Director. These leadership updates aim to strengthen corporate governance.
Natural Capsules Limited allotted 25,000 equity shares under its ESOP scheme. The issuance increases the company's paid-up share capital to ₹10.41 Crore.
Natural Capsules' subsidiary approved a ₹1.11 Crore rights issue. The issuance of 11,11,200 equity shares at par will support subsidiary-level capital requirements.
Natural Capsules Ltd reported revenue from operations of ₹58.5 Cr (+30.0% YoY) and a net loss of ₹5 Cr for Q4 FY26.
Natural Capsules Limited approved its FY26 audited financial results and allotted 25,000 shares under its ESOP plan. Net profit for the year stood at ₹11.21 Crore.
Natural Capsules scheduled a board meeting on May 27, 2026, to approve audited financial results. The trading window remains closed until 48 hours after declaration.
Natural Capsules Limited confirmed it does not meet the SEBI criteria for 'Large Corporate' classification for FY 2025-26. Consequently, the mandatory incremental borrowing requirements through debt securities are not applicable to the company.
Natural Capsules Limited submitted its initial disclosure under the SEBI Large Corporate framework for FY 2026. The company reported outstanding borrowings of ₹23.38 Crore and maintains a BB+ (Stable) credit rating from ICRA. Based on the applicability criteria, the company confirmed it does not currently qualify as a Large Corporate.
Ms. Pranjal Deshmukh has resigned as Company Secretary and Compliance Officer of Natural Capsules Limited, effective April 25, 2026. The resignation is to pursue better career opportunities. The company will need to appoint a successor to fulfill its regulatory compliance requirements.